PIK3CAH1047R-induced paradoxical ERK activation results in resistance to BRAFV600E specific inhibitors in BRAFV600E PIK3CAH1047R double mutant thyroid tumors. by Rölli, Matthias Andreas et al.
Oncotarget103207www.impactjournals.com/oncotarget
www.impactjournals.com/oncotarget/         Oncotarget, 2017, Vol. 8, (No. 61), pp: 103207-103222
PIK3CAH1047R-induced paradoxical ERK activation results 
in resistance to BRAFV600E specific inhibitors in BRAFV600E 
PIK3CAH1047R double mutant thyroid tumors 
Matthias A. Roelli1, Dorothée Ruffieux-Daidié1, Amandine Stooss1, Oussama 
ElMokh1, Wayne A. Phillips3, Matthias S. Dettmer2 and Roch-Philippe Charles1
1Institut für Biochemie und Molekulare Medizin, Universität Bern, Bern, Switzerland
2Institut für Pathologie, Universität Bern, Bern, Switzerland
3Cancer Biology Laboratory, Peter MacCallum Cancer Centre, Melbourne, Australia
Correspondence to: Roch-Philippe Charles, email: roch-philippe.charles@ibmm.unibe.ch
Keywords: aggressive thyroid cancer, BRAFV600E inhibitor resistance, PI3’K inhibitors, paradoxical ERK activation, 
 overcoming resistance
Received: January 17, 2017    Accepted: September 23, 2017    Published: October 11, 2017
Copyright: Roelli et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 
3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
ABSTRACT
Thyroid carcinomas are the most prevalent endocrine cancers. The BRAFV600E 
mutation is found in 40% of the papillary type and 25% of the anaplastic type. 
BRAFV600E inhibitors have shown great success in melanoma but, they have been, to 
date, less successful in thyroid cancer. About 50% of anaplastic thyroid carcinomas 
present mutations/amplification of the phosphatidylinositol 3’ kinase. Here we 
propose to investigate if the hyper activation of that pathway could influence the 
response to BRAFV600E specific inhibitors.
To test this, we used two mouse models of thyroid cancer. Single mutant 
(BRAFV600E) mice responded to BRAFV600E-specific inhibition (PLX-4720), while 
double mutant mice (BRAFV600E; PIK3CAH1047R) showed resistance and even signs of 
aggravation. This resistance was abrogated by combination with a phosphoinositide 
3-kinase inhibitor. At the molecular level, we showed that this resistance was 
concomitant to a paradoxical activation of the MAP-Kinase pathway, which could be 
overturned by phosphoinositide 3-kinase inhibition in vivo in our mouse model and 
in vitro in human double mutant cell lines.
In conclusion, we reveal a phosphoinositide 3-kinase driven, paradoxical MAP-
Kinase pathway activation as mechanism for resistance to BRAFV600E specific inhibitors 
in a clinically relevant mouse model of thyroid cancer.
INTRODUCTION
Thyroid cancer is the most frequent form of 
endocrine malignancy. Papillary thyroid cancer (PTC) is 
the most prevalent type of thyroid carcinoma (80%). It is 
moderately aggressive, moderately lymphometastatic and 
has a response rate above 90% to standard radioiodine 
treatment. The main risk is a possible progression (5–
10% of the cases) to more aggressive variants including 
radio-iodine-resistant PTC, poorly differentiated thyroid 
carcinoma and anaplastic thyroid carcinoma (ATC) [1]. 
For ATC, the survival rate is very poor with a median 
survival of 2–7 months after diagnosis and a mortality rate 
of 90% within the first year after diagnosis [2]. Metastases 
can be observed in 10–20% of ATC cases, mainly in 
the lung and bones [3]. However, unlike most cancer 
patients, ATC patients do not predominantly succumb to 
“dissemination” of the disease, but rather to local invasion 
of the tumor into the tracheal space. Undifferentiated 
cancer cells invade the space between the cartilage 
ring and the tracheal epithelium inducing dyspnea and 
suffocation [4]. The thyroid’s localization next to major 
vessels like the carotids makes complete curative resection 
impossible. There is currently no efficient treatment for 
ATC, the disease being highly resistant to radio- and 
chemotherapies, including radioiodine I131 that usually 
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yields excellent therapeutic outcome in other thyroid 
cancers.
BRAF is part of the canonical signaling pathway 
RAS RAFMEKERK hereafter termed MAPK 
pathway. The mutant gene coding for BRAFV600E is found 
in almost 45% of PTCs and 20–40% of ATCs, making 
it the most common genetic alteration in thyroid cancer 
(~40% overall) [5, 6]. Independent models expressing the 
BRAFV600E mutation specifically in the thyroid demonstrate 
that this constitutively active form of the protein leads 
to development of PTC [7, 8], thus confirming the 
importance of the mutation in pathogenesis. More recent 
models show that BRAFV600E can collaborate with p53 
deletion [9] or with PIK3CAH1047R mutation [10] to 
promote PTC progression to ATC. 
The phosphatidylinositol 3’ kinase or PI3’K is part 
of the RAS PI3’KAKT mTOR pathway hereafter termed 
PI3’K pathway. PI3’K phosphorylates phosphoinositides 
on the 3 position of the inositol ring [11] resulting in AKT 
recruitment to the membrane and its phosphorylation [12]. 
There are several PI3’K which are heterodimers composed of a 
catalytic and a regulatory subunit. PIK3CA codes for the p110α 
catalytic subunit of class I PI3’K [13]. The PIK3CAH1047R 
mutation renders the protein constitutively active and can be 
frequently found in cancers [14]. PI3’K signaling alterations 
frequently occur in aggressive thyroid cancers with 40% gene 
amplification and 20% mutations [15, 16].
Pharmacological mutation specific inhibition of 
BRAFV600E with vemurafenib leads to a dramatic tumor 
regression in melanoma patients [17–19]. Unfortunately, 
half of the patients relapse after six months of treatment. 
Many routes to acquired resistance have been proposed, 
including elevated expression of CRAF [20] or BRAF 
kinases or aberrant expression of a BRAF splice variants 
[21–23]. All these resistance mechanisms lead to the 
reactivation of RAF kinases. In addition, several other 
means of acquired resistance are described, involving 
mutations in other partners of the MAPK pathway such 
as N-RAS [24] or MEK [25]. Remarkably, all these 
mechanisms result in MAPK pathway reactivation, as 
demonstrated by ERK phosphorylation, and eventually 
lead to a resumption of tumor growth. This emphasizes 
the central role of the MAPK pathway as the main driver 
of tumor growth and resistance and the necessity to 
pharmacologically target that pathway to achieve tumor 
reduction.
Even though 40% of all thyroid tumors harbor 
the BRAFV600E mutation, unlike in melanoma, it is 
not clear whether BRAFV600E inhibition could be used 
against thyroid tumors. About 10% or thyroid cancers 
are incurable because of diffuse presentation that make 
them inoperable as well as their loss of iodine hunger. 
New targeted therapies are therefore urgently needed 
for ATC and radio-iodine-resistant PTC. There are some 
encouraging results from single case studies in BRAFV600E 
positive ATC [26, 27] and also for invasive BRAFV600E 
positive PTC albeit from reports of very small cohorts 
[28]. The biggest study so far concerns 7 ATC patients 
with various responses from complete/partial regression 
but surprisingly also to tumor progression [29]. Overall 
these studies suggest an approximate 50% response rate 
to BRAFV600E inhibitors in aggressive thyroid cancer. One 
case even showed patient’s rapid worsening which is the 
actual opposite of what was expected after vemurafenib 
treatment [27]. This suggests “pre-existing” drug 
resistance that does not result from treatment adaptation 
over a few weeks as it is the case in melanomas. 
Understanding these refractory forms of cancer is 
essential for efficient use of targeted therapies. In this 
study, we used a BRAFV600E PIK3CAH1047R double mutant, 
as well as a BRAFV600E single mutant mouse model to 
investigate the tumor burden response to BRAFV600E 
specific inhibition. Our experiments showed that the 
PIK3CAH1047R mutation conferred resistance to the drug. 
This resistance was waived by combination treatment 
with a PI3’K inhibitor. The resistance was correlated 
to paradoxical hyperactivation of ERK, that was also 
depending on PI3’K activity.
RESULTS
BRAFV600E single mutant thyroid tumor respond 
to PLX4720 inhibition, while BRAFV600E; 
PIK3CAH1047R double mutant tumors do not
Our primary aim was assessing the effect of 
BRAFV600E inhibition in our two mouse models. The 
BRAFV600E single, and the BRAFV600E/PIK3CAH1047R 
double mutant. PLX-4720, a commonly used pre-clinical 
surrogate for vemurafenib [30–32] that is similarly potent 
but more soluble/bioavailable [33] was used to inhibit 
BRAFV600E specifically.
Mice were bred, tumors induced at the age of one 
month and the treatments started two months after tumor 
induction to allow tumors to form (Figure 1A), but still 
leave enough time to treat mice for 3 more months without 
reaching 6 months after induction when mice usually 
reach endpoint (whistling, breathing issues and consequent 
sudden weight loss) (Figure 1A).
In single mutant mice, the PLX-4720 drug treatment 
induced a significant tumor size reduction (-20%) that 
lasted for more than 10 weeks, while controls increased 
in size by more than 50% (Figure 1B). In double mutant 
mice, tumors were bigger and grew faster than in single 
mutant. The control group grew rapidly and steadily 
during the 10 weeks of monitoring. PLX-4720 treated 
animals had a modest drug response for 3 weeks (-10%), 
then tumor burden resumed growth at a similar rate 
to control mice with a tumor burden increase of +12 
percentage points per week (Figure 1C and 1D). Much 
to our concern, 3 out of 5 animals from this group had 
to be removed (crosses on Figure 1C) during the course 
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of the experiment as they were reaching predefined 
endpoint criteria (see above paragraph). This worsening 
of the condition was only witnessed in PLX-4720 treated 
animals. GDC-0941 treated animals presented an initial 
tumor burden reduction of 20% then tumor size stabilized 
for the rest of the treatment period. Interestingly, when 
a drug combination of PLX-4720 and GDC-0941 was 
administered, mice showed a robust response with 60% 
lower tumor burden after 6 weeks followed by stabilization 
until the end of the experiment (Figure 1C and 1D).
Double mutant tumors present histological 
worsening after BRAFV600E specific inhibition
After 10 weeks of treatment, 3 double mutant 
mice per group were dissected and their thyroids were 
processed for histological analysis. Control mice had the 
expected histology (Figure 2A): aggressive PTC with tall 
cell variant (Figure 2A middle), and foci presenting signs 
of phenotypic progression to ATC (Figure 2A bottom). 
GDC-0941-treated mice had smaller thyroid sections, 
while presenting a similar histology compared to controls 
(Figure 2B) with a mixture of PTC (Figure 2B middle) 
containing small ATC foci (Figure 2B bottom). Animals 
treated with the drug combination also presented smaller 
thyroid sections but in these PTC areas were almost absent 
(Figure 2C), leaving connective tissue (Figure 2C middle) 
and cholesterol clefts, but ATC foci remained (Figure 2C 
bottom). 
PLX-4720-treated thyroids (Figure 2D) presented 
large PTC nodule areas that were more solid and featuring 
areas of the hobnail type of PTC (Figure 2D Middle) 
and large areas of ATC (Figure 2D bottom). In early 
terminated PLX-4720 animals (Figure 2E), while areas of 
PTC persist (Figure 2E middle) larger ATC areas could 
be found (Figure 2E Middle), invading the surroundings 
muscles (Figure 2E bottom), and eventually the tracheal 
rings. Overall, they looked more progressed than any 
other group. Immunostainings were preformed to confirm 
the pathological analysis. PTC areas were positive for 
galectin-3 and cytokeratin 19 while ATC areas were 
positive for galectin-3 and vimentin (Figure 2F).
Double mutant tumors present paradoxical 
activation of ERK after 10 weeks of PLX-4720 
treatment
Signaling pathways in the tumors were investigated 
by western blot. PLX-4720-treated animals displayed 
an unexpected paradoxically elevated ERK1/2 
phosphorylation ratio compared to the controls after 10 
weeks of treatment. When treated with GDC-0941 alone, 
ERK1/2 phosphorylation was unchanged compared to 
controls. When treated with drug combination, ERK 
paradoxical activation was abolished resulting in ERK 
phosphorylation level comparable to controls. AKT 
phosphorylation was not affected by PLX-4720 while 
GDC-0941 treatment resulted in a small but significant 
reduction of AKT phosphorylation (Figure 3A). 
For comparison, we performed western blots with 
proteins extracted from BRAFV600E single mutant mice. 
In this case, after 70 days of PLX-4720 treatment, ERK 
phosphorylation in treated animals was comparable to 
the non-treated. As expected, PLX4720 treatment did not 
affect AKT phosphorylation significantly (Figure 3B).
Paradoxical activation of ERK also occurs after 
short periods of PLX-4720 treatment
To confirm the observed paradoxical ERK 
activation, we treated mice with the same drugs for a 
shorter period of 10 days. We observed the same trend 
for tumor burden as seen after 10 weeks (Figure 4A). 
Only GDC-0941 and drug combination treated animals 
showed tumor burden reduction. PLX-4720 treated 
animals displayed a tumor burden that was not statistically 
different from the controls but appeared elevated from the 
two other groups (Figure 4A). 
Similarly, to the observed effect at 10 weeks, after 
10 days of treatment we observed paradoxical activation 
of ERK under PLX-4720 treatment that was abrogated by 
the drug combination (Figure 4B). To complete this part, 
we also treated double mutant animals only once with 
PLX-4720 or GDC-0941 and dissected the animals four 
hours after drug administration. At this time, the PLX-
4720 driven paradoxical activation of ERK was already 
observable. GDC-0941 treatment on the other hand led to 
a pronounced de-phosphorylation of AKT.
Finally, to ensure that ERK phosphorylation 
signal was coming from tumor cells, we performed 
immunofluorescence staining on tumor samples. The 
signal was clearly located in the tumor cells and not in 
the mesenchyme or coming from infiltrating immune cells. 
The specificity of our staining was verified by treating 
mice with the potent MEK1/2 inhibitor PD-325901 [34] 
that completely abrogated ERK phosphorylation after 10 
consecutive days of treatment (Figure 4C).
Drug combination induces increased cell death 
in vivo
Searching for the mechanisms driving the observed 
tumor reduction, we performed immunofluorescence 
staining for Ki67. We could only detect a significant 
increase of Ki67 index in PLX-4720 treated animals 
compared to the drug combination group (Figure 5A). 
Then we performed TUNEL staining to monitor DNA 
fragmentation. The count of apoptotic bodies was 
increased in GDC-0941 and drug combination treatment 
(Figure 5B). In addition, we detected a reduced count in 
PLX-4720 treated tumors. We then performed a Masson’s 
trichrome staining to evidence collagen accumulation 
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stained in blue (Figure 5C). Interestingly, the drug 
combination treatment led to a significantly increased 
proportion of collagen rich areas inside the thyroid lobes, 
evidencing higher tumor regression. Tumors from PLX-
4720-treated mice had a significantly lower proportion of 
collagen in the tumor tissue. 
Paradoxical activation of ERK under BRAFV600E 
specific inhibition treatment is also PI3’K-
dependent in human ATC cell lines
To further demonstrate that paradoxical activation of 
ERK also depends on PI3’K signal in human ATC cells, 
Figure 1: PI3’K inhibition counteracts PLX-4720 resistance in a double mutant thyroid cancer mouse model. (A) 
Schematic timeline depiction of in vivo Experiment. Tumor burden in single mutant BrafCA/+; ThyroglobulinCreERT2 mice (B) and double 
mutant BrafCA/+; Pik3caLat/+; ThyroglobulinCreERT2 mice (C) in percentage of the tumor burden at the beginning of the drug treatment. 
Crosses represent events of mice reaching end-point criteria. (D) Representative pictures from ultrasound imaging of double mutant mice 
after 70 days of treatment used for assessment of the tumor burden. Thyroid outlines are shown by blue lines.
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we used three cell lines. OCUT-2 cells harbor the same 
mutations as the double mutant mouse model (BRAFV600E/
PIK3CAH1047R), whereas 8505c and SW1736, analogous to 
the single mutant mice, only have the BRAFV600E mutation. 
The mutational status of PIK3CA in these cell lines was 
confirmed by sequencing [35]. As paradoxical ERK 
activation has been described to be dependent on drug 
concentration [36], we exposed the cells to decreasing 
concentrations of PLX-4032 (vemurafenib). Interestingly, 
OCUT-2 cells had a greater than 2-fold increase in p-ERK/
Figure 2: Histological presentation of tumors after 70 days of drug treatments. H and E staining from formalin fixed paraffin 
embedded and sectioned (5 μm) thyroids from double mutant mice after 70 days of treatment. Representative thyroid tissues at the end of the 
treatment of (A) control, (B) 50 mg/kg GDC-0941, (C) drug combination (50 mg/kg GDC-0941 and 30 mg/kg PLX-4720 and (D) 30 mg/
kg PLX-4720 treated mice. (E) H and E staining of thyroid tissues from a double mutant mouse treated with PLX-4720 reaching endpoint 
after 36 days of treatment. Scale bars: 500 µm (upper panels) 50 µm (middle and lower panels). (F) Immunostainings of representative 
PTC and ATC tissues stained for Cytokeratin 19 (red) DAPI/nuclei (blue) and either Galectin-3 or Vimentin (green). Scale bars 100 µm.
Oncotarget103212www.impactjournals.com/oncotarget
tot-ERK ratio compared to vehicle treated cells, at low 
concentrations: 1.6 and 8 nM (Figure 6A). Paradoxical 
ERK hyper-phosphorylation was not detectable when 
cells were subjected to GDC-0941 in addition to PLX-
4032 drug dilutions. When we treated them with the same 
concentrations of PLX-4032, 8505c and SW1736 cells did 
not exhibit paradoxical ERK activation (Figure 6B). The 
additional treatment with GDC-0941 did not affect either 
the baseline ERK phosphorylation or the response to PLX-
4032 regardless of the PLX-4032 concentration in 8505c 
cells. To strengthen this point, we have also performed 
a similar experiment using BKM-120, another PI3’K 
inhibitor (Supplementary Figure 1). In this case, BKM-120 
similarly abrogated the paradoxical effect seen in OCUT-2, 
demonstrating that the phenomenon observed is unlikely to 
be caused by a possible off-target effect of GDC-0941 but 
was rather specific to its inhibitory effect on PI3’K activity.
DISCUSSION
The BRAFV600E mutation is detected in many 
cancer types such as melanoma, colon, ovarian, lung and 
prostate cancers [37, 38]. In general, it accounts for 8% 
of all mutations in human cancers [37]. The development 
of specific inhibitors against this mutation has raised a 
lot of interest in the clinics, for its potential lack of side 
effects. There is a strong rational to translate the success of 
vemurafenib from melanoma to other BRAFV600E positive 
tumors like PTC or ATC. Unfortunately, case studies using 
vemurafenib in aggressive invasive-PTC and ATC show 
diverse results ranging from regression to no response or 
even aggravation [26–29].
We showed here that BRAFV600E inhibition 
presented the expected response in BRAFV600E single 
mutant mice (Figure 1B). Tumor burden decreased at 
first then reached a plateau, reflecting the fact that after 
an initial response phase, MAPK signaling is transduced 
through BRAFWT restoring a “normal” level of ERK 
phosphorylation (Figure 3B) resulting in no further 
clinical benefit of the drug. This was rather expected. 
On the other hand, when subjected to the same dose 
of PLX-4720, BRAFV600E PIK3CAH1047R double mutant 
tumors regrew after a very short initial response (Figure 
1C). This suggests that the additional PIK3CAH1047R 
mutation resulted in a rapid resistance to BRAFV600E 
specific inhibition. This was confirmed by the resistance 
break obtained by the inhibition of PI3’K activity with 
the addition of GDC-0941 to the treatment regime. 
Consistently, recent studies in a model of colorectal 
cancer have shown that resistance to PLX-4720 treatment 
in vivo can be relieved by inhibition of PI3’K [39].
The initial phase of tumor reduction after PLX-4720 
treatment in the double mutant model can be explained by 
tumor heterogeneity. Indeed, in this mouse model, tumors 
consist of rare normal follicles amongst large PTC and 
ATC foci (Figure 2A–2E). Full Cre-driven recombination 
of both alleles from latent to mutant might not have 
occurred in every original cell. A portion of the tumors 
might be BRAFV600E-single mutant and still be responsive 
to PLX-4720. Interestingly, in the second double mutant 
cohort of mice, the resistance to PLX-4720 was already 
detectable after 10 days of treatment most likely due to a 
smaller proportion of single mutant cells. GDC-0941 and 
drug combination on the other hand already displayed a 
significantly tumor reduction effect (Figure 4A), 
Even though treatment with GDC-0941 clearly 
induced a 20% reduction in the size of the tumor 
(Figure 1C), possibly due to apoptosis elevation 
Figure 3: BRAFV600E and PIK3CAH1047R tumors present a paradoxical activation of ERK under PLX-4720 treatment 
after 10 weeks. (A) Representative pooled western blot (left), and quantification of single sample blots (right) of proteins from BRAFV600E/
PIK3CAH1047R double mutant mice treated for 70 days with either vehicle, PLX-4720 (30 mg/kg), GDC-0941 (50 mg/kg) or a combination 
of both. (B) Representative pooled western blot (left), and quantification of single sample blots (right) of proteins from BRAFV600E single 
mutant mice treated for 76 days with either vehicle or PLX-4720 (30 mg/kg). Error bars represent standard deviation. Values represent 
means of calculated ratios. Points represent single ratio values.
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(Figure 5B and 5C), there was no clear beneficial effect 
in terms of histology (Figure 2B). In terms of pathways 
activation, AKT phosphorylation level was reduced 
profoundly after 4 hours (Figure 4B) but the effect seemed 
weaker after 10 days (Figure 4B) and 10 weeks (Figure 
3A) of treatment. This suggests that there are mechanisms 
of adaptation in this pathway as well, allowing restoration 
of AKT phosphorylation even when PI3’K is inhibited. 
The fact, that there is still a cytostatic effect when treating 
with GDC-0941, even though AKT phosphorylation 
level has partially recovered, demonstrates that AKT 
phosphorylation and PI3’K activity/mutation are not 
necessarily linked in this context [40]. This suggests, that a 
mechanism downstream of PI3’K that does not necessarily 
involve AKT could be responsible for tumor promotion. 
These findings are consistent with a recent publication 
from our group were PI3’K inhibition was combined with 
the MEK inhibitor PD-325901 [35].
Our most unexpected observation was that double 
mutant mice treated with PLX-4720 alone displayed a 
strong increase in ERK phosphorylation (Figure 3A) after 10 
weeks, that goes beyond recovery of ERK signaling that was 
also observed 10 days and 4 hours after treatment (Figure 
4B). We confirmed this by immunofluorescence staining, 
where PLX-4720 treatment triggered an increase in the 
P-ERK signal in tumor cells (Figure 4C). BRAFV600E specific 
inhibition has been showed before to decrease P-ERK1/2 
at first, then ERK activity will be restored by releasing the 
feedback inhibition loop between ERK and RAS, allowing 
“normal” RAF signaling through the wild-type allele of 
BRAF, as shown in our single mutant mice (Figure 3B). 
The over-activation that we observe in the context of our 
PLX-4720 treated double mutant mice is however more 
reminiscent of the “paradoxical effect” of RAF inhibitors 
[41]. This paradoxical effect was described in melanoma 
patients treated with vemurafenib who developed squamous 
cell carcinoma [42] and explained by aberrant dimerization 
and enhanced signaling through BRAFWT and CRAF. [43–
46] Interestingly, this effect has been suggested to be used 
beneficially in wound healing [47].
The elevated ERK activation in the present study 
explained the worsening of the condition of the double 
mutant mice treated with PLX-4720 (Figure 2E). 
Interestingly, in order to take place, paradoxical ERK 
activation requires an activating signal upstream of CRAF. 
In this case, CRAF (also called Raf-1) could be activated 
by PI3’K [48]. Paradoxical ERK activation is most likely 
also the cause for the observed elevation of Ki67 in the 
tumors of PLX-4720 treated double mutant animals 
(Figure 5A). The elevation of the Ki67 index could also 
be caused by the observed ATC progression of the tumors 
of PLX-4720 treated animals, since ATC presents a 
dramatically elevated proliferation index compared to well 
differentiated thyroid cancers. The progression to ATC is 
furthermore evidenced by the decreased TUNEL (Figure 
5B) and decreased collagen deposition (Figure 5C) since 
ATC are refractory to drug-induced apoptosis. One could 
speculate that a paradoxical ERK activation might also 
have been responsible for tumor progression in a reported 
case of rapid tumor progression observed when an ATC 
patient was treated with vemurafenib [27]. 
To assess whether this paradoxical ERK 
hyperactivation was transcriptionally regulated, we treated 
tumor-bearing mice with one dose of PLX-4720 and 
dissected tumors 4 hours post treatment. The paradoxical 
effect could already be observed at that point (Figure 4B 
and 4C) advocating for a non-transcriptionally regulated 
effect. Altogether this data suggests that paradoxical ERK 
activation is non-transcriptionally regulated and PI3’K 
dependent. 
In vitro, the paradoxical effect was only observed in 
the OCUT-2 cell line (Figure 6A) that has the same mutation 
pattern as the double mutant BRAFV600E/PIK3CAH1047R mice 
but not in 8505c or SW1736 cells, (Figure 6B) that have no 
Figure 4: BRAFV600E and PIK3CAH1047R tumors present a paradoxical activation of ERK under PLX-4720 treatment 
also after 10 days. (A) Tumor burden quantification from BRAFV600E/PIK3CAH1047R double mutant mice treated for 10 days with either 
vehicle, PLX-4720 (30 mg/kg), GDC-0941 (50 mg/kg) or a combination of both, (B) Representative pooled western blot (left), and 
quantification of single sample blots (right) of proteins from the same animals and from animals treated only once with either PLX-4720 
(30 mg/kg), GDC-0941 (50 mg/kg) and dissected 4 hours later. (C) Immunofluorescence staining for P-ERK of formalin fixed, paraffin 
embedded thyroid tumor samples sectioned to 5μm from BRAFV600E, PIK3CAH1047R double mutant mice treated with either vehicle, PLX-
4720 (30 mg/kg or PD-325901 (5 mg/kg) for 10 days or PLX-4720 (30 mg/kg) for 4 hours. Scale bars: 100 µm.
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Figure 5: Drug combination induces increased cell death in vivo. Ki67 staining formalin fixed, paraffin embedded 5 μm tumor 
samples (A) Left side: Representative immunofluorescence after 70 days of treatment. DAPI (blue) Ki67 (green). Scale Bars: 100 μm. Right 
side: Quantification on whole tumors averaged from 4 consecutive sections. (B) Left side: TUNEL staining revealed with streptavidin-
Alexa633 fluorescent probe (purple) and DAPI (blue). Scale Bars: 100 μm. Right side: TUNEL positive nuclei normalized to total nuclei 
counts. Scale bars: 100 µm. (C) Top: Representative images of Masson’s trichrome stained tumor sections and higher magnifications 
thereof below. Scale bars: 1 mm (upper) and 50 µm (lower). Bottom: evaluation of collagen rich area normalized to total tissue area per 
tumor. Error bars represent standard deviation. Values represent means of calculated ratios. Points represent single ratio values.
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reported alteration in PI3’K. The latter cell lines represent 
the single mutant mice, that did not show venurafenib 
induced paradoxical activation either. Consistently, 8505c 
used in an orthotropic xenograft model were responding 
to PLX-4720 treatment in vivo [49]. The observed effect 
of paradoxical ERK activation in OCUT-2 cells could 
again be prevented when cells were concomitantly treated 
with GDC-0941 (Figure 6A), once more showing that 
paradoxical ERK hyper-activation is dependent on PI3’K 
activity. It is important to note that the paradoxical effect is 
dependent on drug concentration and might therefore have 
been missed in several studies using 1 µM PLX-4032. This 
can be explained by the fact that at this concentration, PLX-
4032 inhibits all RAF isoforms and therefore also blocks 
CRAF, which is required for paradoxical activation. 
Drug combination treatment presented the 
strongest effect on tumor burden (Figure 1C). Looking 
at TUNEL staining, GDC-0941 and drug combination 
treated animals could not be distinguished (Figure 5B). 
Apoptosis is a short-term process of programmed cell 
death. In general, cell debris disappears by extracellular 
enzyme digestion and leukocyte phagocytosis and 
is replaced by accumulation of fibrotic tissue. This 
is measured in daily clinical practice as response to 
chemotherapy in so-called regression scores in various 
human tumor types [50–52]. Deposition of fibrotic tissue 
was measured by Masson’s trichrome staining (Figure 
5C). Masson’s Trichrome staining showed significantly 
less deposition of fibrotic tissue in GDC-0941 treated 
animals, compared to combination treated animals. 
This revealed a slightly increased rate of cellular death 
in combination treated, compared to GDC-0941 treated 
animals that could only be visualized by a method that 
measures the accumulative effect of cell death. Whether 
this was due to apoptosis, necrosis or a different type 
of cell death remains unclear. With a similar Ki67 
index, and TUNEL count (Figure 5), a further cell 
death mechanism might be involved under combination 
treatment (e.g. necrosis). It is also important to note that 
the areas that were mainly affected consisted of PTC, 
as demonstrated by the absence of PTC in tumors of 
combination treated animals. ATC foci remained (Figure 
2C), meaning that this drug combination was mostly 
effective on PTC, but the effect on ATC remains elusive 
and would require more work in vivo.
Our data led us to propose the following mechanism 
for PLX-4720-induced ERK paradoxical activation and 
therefore resistance: BRAFV600E specific inhibition leads to an 
increased formation of an active B/CRAF heterodimer and 
the complex is further stimulated by PI3’K [43–46, 48, 53] 
resulting in increased ERK phosphorylation as schematically 
presented in Figure 7. The two events, stabilization of a 
BRAFV600E/CRAF complex by BRAFV600E specific inhibitors 
and activation of CRAF through PI3’K, are required to 
obtain paradoxically hyper-phosphorylated ERK1/2 that led 
to the worsening of the phenotype (Figure 1). Our data are 
consistent with the fact that RAS activates PI3’K, and that 
newly arising skin tumors in vemurafenib treated BRAFV600E 
mutant melanoma patients often carry activating mutations 
in RAS [42]. This novel in vivo mechanism of resistance 
clearly differs from published resistance mechanisms in 
melanoma, where resistance seems to be acquired during 
the course of treatment [20, 21, 23]. Such treatment-induced 
adaptive mechanism was also described in the context of 
thyroid cancer were thyroid cancer cells show resistance 
to vemurafenib that was induced by up-regulation and 
activation of HER-3 [54]. Our data, thus, uncover a novel 
mechanism of vemurafenib resistance.
Regardless of the paradoxical resistance, while 
being beneficial, BRAFV600E inhibition shows some limits, 
since profound ERK inhibition cannot be maintained even 
in combination with GDC-0941. MEK1/2 inhibition is 
able to produce a sustained and deep MAPK inhibition in 
thyroid [55]. But unlike vemurafenib the toxicity of MEK 
inhibition does not allow long periods of treatment. The 
option to combine both inhibitors to achieve lower toxicity 
might become the standard care in melanoma [56]. But 
another approach is to alternate cycles of vemurafenib 
and drug vacancy to perturb the adaptive signaling to 
BRAFV600E inhibition [57].
Finally, our findings suggest that selecting patients 
for targeted therapies based on their BRAF mutational 
status alone is not sufficient for choosing a successful 
therapy. The mutational status of PIK3CA should also be 
assessed, as treating BRAFV600E positive patients carrying 
activating PI3’K mutations with BRAFV600E-specific 
inhibitors may lead to ERK hyper-activation and disease 
aggravation. Gene amplification measurements should also 
be considered, since more patients seem to be resistant 
to vemurafenib than suggested by the PI3’K activating 
mutation frequency alone. In conclusion, we suggest an 
explanation for the observed high rate of a priori drug-
resistance to BRAFV600E specific inhibitors seen in thyroid 
cancer. Nevertheless, we show that treating patients with 
BRAFV600E inhibitors such as vemurafenib could be a 
valid approach in the appropriate clinical setting including 
prior mutational testing of the tumor and, if applicable, 
administered alone or combined with PI3’K inhibitors. 
The combination of both PI3’K and BRAFV600E inhibition 
may lead to a stronger response and should therefore be 
considered in the clinics, since a clear collaborative effect 
is visible in vivo. On the other hand, the coming of the new 
generation of paradox-evading RAF inhibitors [58] might 
waive the resistance mechanism that we described here 
and open the way to a broader use of RAF inhibitors in the 
context of aggressive inoperable PTC, and ATC.
MATERIALS AND METHODS
Cell lines
The BRAFV600E mutant ATC cell lines 8505c and 
SW1736 were purchased at the Public Health England 
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repository and cultured in RPMI-1640, 10% FCS, 2 
mM L-glutamine, MEM NEAA (Thermo Fisher) 1:100 
and P/S (100U Penicilin/ml and 0.1mg Streptomycin/
ml). The ATC cell line OCUT-2 carries concomitant 
BRAFV600E and PIK3CAH1047R mutations [59]. It was kindly 
provided by Prof. James Fagin (Memorial Sloan Kettering 
Cancer Center), validated by our group by STR profiling 
(Microsynth, Switzerland), and cultured in DMEM medium 
10% FCS, 2 mM L-glutamine, MEM NEAA (Thermo 
Fisher) 1:100 and P/S (100U Penicilin/ml and 0.1mg 
Streptomycin/ml). The mutational status for PIK3CA of all 
three cell lines was validated by sequencing. All cell lines 
were cultured for a maximum of 40 passages or 6 months; 
whichever limit was reached first.
Drugs used
PLX-4720, PLX-4032 (vemurafenib), GDC-0941, 
PD-0325901 and BKM-120 were purchased from Abmole 
Bioscience, Hong-Kong.
Mice
All mouse experiments were performed in 
compliance with Swiss federal legislation and licensed by 
the Kanton of Bern. License Nr: BE120–13. Mice were 
kept in isolated ventilated cages, fed ad libitum in a 12/12 
hours cycle of light and dark.
Drug administration, mutations induction and 
tumor burden assay
BrafCA/+; ThyroglobulinCreERT2 single mutant 
or BrafCA/+; Pik3caLat/+; ThyroglobulinCreERT2 double 
mutant mice from a mixed FVB/C57BL6/F129 
background were bred and mutations were induced 
by daily intraperitoneal injections of 1 mg tamoxifen 
diluted in peanut oil (100 µL) on five consecutive days. 
After two months of tumor growth, tumor bearing mice 
were treated by oral gavage with 30 mg/kg PLX-4720, 
50 mg/kg GDC-0941 or the combination of both, or 5 
mg/kg PD-0325901 formulated in a solution of 0.5% 
Hydroxypropylmethylcellulose (HPMC) (Sigma H7509) 
and 0.2% Tween 80 (Sigma P4780) six days per week. 
All mice weighed between 20 and 30 g at the start of 
the experiment. Group allocation for drug treatments 
was done randomly. Group size was determined using 
a power calculation assuming the following parameters: 
difference: 20%; variation: 20%; a 5%; b 50%. 
Beginning on the first day of drug treatment, tumors 
were measured by ultrasound measurement every week. 
For ultrasound measurements mice were anesthetized 
Figure 6: Paradoxical activation of ERK under BRAFV600E specific inhibition treatment is also PI3K-dependent in 
human ATC cell lines. Representative western blots from total protein extracted from OCUT-2 (A) and 8505c (B) cells exposed to 
decreasing concentrations of PLX-4032 (from 1 µM to 1.6 nM) in presence or absence of GDC-0941 at 1 µM. All experiments were 
performed in triplicate and the quantifications are expressed as average ratios of the three independent experiments (C). The western blot 
of 8505C stands as a representative for both BRAFV600E single mutant cell lines. 
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using 5 μl/g of body weight of a mixture of 0.1 mg/ml 
Dorbene, 0.5 mg/ml Dormicum and 5 μg/ml Fentanyl in 
0.9% NaCl by intraperitoneal injection. The fur around 
the neck was epilated with Veet® hair removal cream. 
Pictures were acquired with an ESAOTE MyLab Five 
ultrasound machine using a LA455 Probe (18 Mhz) 
from Siemens. After imaging, mice were taken out of 
anesthesia with 10 μl/g body weight of a mixture of 0.25 
mg/ml Alzan, 5 μg/ml Flumazenil and 20 μg/ml Naloxon 
in 0.9% NaCl by subcutaneous injection. Images were 
analyzed using the ImageJ software. Evaluation of 
tumor burden was performed by the experimenter by 
measuring the surface of the biggest cross section in 
mm2 and normalized to the starting tumor burden of each 
mouse for comparison.
Total protein preparation from cells
Cells were washed twice with cold PBS, recovered 
by scraping, then lysed in triton lysis buffer (150 mM 
NaCl, 50 mM Tris-HCl pH 7.4, 1 mM EDTA pH 8.0, 
1% Triton-X-100) complemented with Halt™ Inhibitor 
Cocktail 1:100 (Pierce, ThermoFischier Scientific). The 
lysates were incubated 30 min on ice and then cleared 
by 15 min of centrifugation at 16,000 g at 4 °C. Protein 
concentrations were quantified by the BCA method (BCA 
Figure 7: Schematic representation of RAF paradoxical activation. (A) In physiological conditions, upon Receptor Tyrosine 
Kinase (RTK) activation, receptor clustering induces RAS recruitment to the membrane. This results in dimerization of B/CRAF and 
subsequent phosphorylation that, in fine, induces ERK phosphorylation. (B) When BRAF is mutated to BRAFV600E it is able to dimerize 
without RAS recruitment and induce ERK activation independently from upstream signals. ERK activation results in Sprouty’s up-
regulation (SPRY) and therefore moderation of the pathway. (C) When treated with PLX-4720, BRAFV600E is stabilized in a form that 
allows its dimerization with CRAF. This complex is then further stimulated by hyperactive PI3’K, leading to paradoxical ERK activation.
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Protein Assay Kit, Pierce, ThermoFischer Scientific). 
Lysates were prepared at 1-4 µg/µl in sample buffer (0.294 
M sucrose, 2% SDS, 1 mM EDTA, 60 mM Tris pH 8.8, 
0.05% Bromophenol blue, and 26 mM dithiothreitol) and 
the proteins analyzed by western blotting (see below).
Total protein preparation from mice
Tissues were resected from anesthetized mice (10 mg/
ml of Ketamin and 1.6 mg/ml Xylazin, at a dose of 10 µl/g 
body weight by intraperitoneal injection). After resection, 
the tissues were washed in ice-cold PBS (137 mM NaCl; 
2.7 mM KCl; 18mM KH2PO4; 100mMNa2HPO4), snap 
frozen in liquid nitrogen and stored at -80°C until protein 
extraction. Proteins were extracted from tissue using 
RIPA buffer (20 mM Tris-base pH 8.0, 150 mM NaCl, 
1% Triton-X-100, 0.1% SDS, 0.5% deoxycholate Na+). 
Halt™ Inhibitor Cocktail was added to the RIPA buffer to 
prevent dephosphorylation and protein degradation. 100 µl 
of RIPA plus Halt was added to the tissue samples for lysis 
using a QIAGEN TissueLyser LT at 50 Hz until complete 
homogenization (1–2 min). For large pieces of tissue, the 
amount of lysis buffer was increased. After complete tissue 
disruption, the sample was incubated on ice for 30 min and 
then centrifuged for 30 min at 4°C and 17,000 g. Protein 
concentration of the supernatant was evaluated as described 
above. All animals were euthanized 4 hours after their last 
drug administration.
Western blotting
Protein extracts were either loaded separately (for 
quantifications) or pooled (for figure pictures) for each 
treatment condition. Proteins were run on TGX precast 
4-20% gels (BioRad, Switzerland), transferred onto Trans-
Blot transfer pack nitrocellulose (BioRad, Switzerland). 
Western blots were probed with the following antibodies 
and concentrations: Primary antibodies (dilution and 
catalogue number) from Cell Signaling (Purchased from 
Bioconcept AG, Switzerland): ERK1/2 (1:5000 9107); 
P-ERK1/2 (1:2000 4370); pan-AKT (1:2000 4691); 
pan-Akt (1:2000 6040); P-AKT-Ser473 (1:2000 4060) 
and b-actin (1:5000 or 1:10’000 A2066). Secondary 
antibodies, Li-Cor Biosciences (Bad Homburg Germany): 
IRDye 680RD Goat anti-Mouse IgG (H + L) (1:10’000, 
926-68071), IRDye 800CW Goat anti-Rabbit IgG (H + 
L) (1:10’000, 926-32210). Blots were scanned using a Li-
Cor ODYSSEY Sa fluorescent western blot scanner and 
quantified with the ODYSSEY Image Studio software.
Immunofluorescence
Tissue samples for histology were recovered 
concomitantly to those recovered for proteins, washed in 
cold PBS and fixed overnight in a neutrally buffered 10% 
formalin solution (Sigma HT501128). Paraffin-embedded 
tissue was sectioned to 5 μm. The sections were rehydrated 
after paraffin removal and targets were retrieved in Tris 
(Sigma T1503) 10 mM, EGTA (Sigma E4378) 0.5 mM 
pH = 8.0 solution. The sections were blocked three times 
for 10 minutes in a buffer of 1% BSA, 0.2% gelatin, and 
0.05% Saponin (Sigma 47036) in PBS. The primary 
antibody KI67 (1:300; Abcam, ab16667) was diluted in 
0.1% BSA and 0.3% Triton X-100 in PBS. Other primary 
antibodies were Ck-19 (1:300; DSHB, 5605s), galectin 
3 (1:300 Abcam ab53082), vimentin (1:300 Bioconcept 
5741S) and P-ERK1/2 (1:300 Bioconcept 4370L) Primary 
antibodies were incubated overnight at 4 °C. The slides 
were then washed three times with 0.1% BSA, 0.2% 
gelatin and 0.05% Saponin in PBS. The secondary 
antibody was goat anti-rabbit 488 (Life Technologies 
A-11034 1:500) complemented by DAPI (Sigma 32670) at 
5 µg/ml to counterstain nuclei and incubated for 1 hour at 
room temperature. Slides were scanned with a Panoramic 
Midi Scanner (Sysmex/3DHISTECH Switzerland/
Hungary). Analysis and quantification was performed 
on whole tumor sections with the Quant Center software 
(Sysmex/3DHISTECH Switzerland/Hungary).
Hematoxylin-Eosin Staining
For histological analysis, tissue samples were 
processed as described above and stained with 
Hematoxylin (Sigma GHS132) and Eosin (HT110132) 
following standard protocols. 
TUNEL
For TUNEL staining tissue was processed and 
sectioned according to the procedure described in the 
preparation of Immunofluorescence slides. Rehydration 
was also done as described in the Immunofluorescence 
section. Sections were pretreated with proteinase K (Sigma 
P2308) with an activity of 0.6 units/ml for 10-20 min in a 
humidifying chamber at 37°C before they were left to cool 
at room temperature for 10 min. Subsequently, sections 
were washed twice in PBS 1x Tween20 (Sigma P9416) 
0.1% for 2 min each. To decrease background signal, 
endogenous biotin was blocked using a kit from Thermo 
Fisher (E21390). Then sections were pre-incubated in 
TdT reaction buffer containing 25 mM TRIS-HCl pH 
6.6 (Sigma T1503), 200 nM Sodium Cacodylate (Sigma 
C0250), 0.25 mg/ml BSA and 1 mM Cobalt Chloride 
(Sigma C8661) for 10 minutes at room temperature. After 
pre-incubation, the sections were incubated in TdT reaction 
mixture for 1–2 h at 37°C in a humidifying chamber. TdT 
reaction mixture contains Terminal deoxynucleutidyl 
Transferase (TdT) (Sigma 3333566001) and Biotin 16-
dUTP (Roche 11093070910). The reaction was stopped by 
incubating the sections with a buffer containing 300 mM 
NaCl (Sigma S9888) and 30 mM sodium citrate (Sigma 
S4641) for 10 min at room temperature. The sections 
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were then washed three times for 2 min in PBS containing 
0.1% Tween20. Before labeling, the slides were blocked 
with a solution of 3% BSA (Sigma A7906) in PBS 1x, 
followed by three washing steps (2 min each) with PBS 
+ Tween20 (0.1%). For detection, slides were incubated 
with a solution containing streptavidin-Alexa Fluor 633 
(1:2000 S21375 from LuBioScience) and DAPI 5 µg/ml 
(32670 Sigma Aldrich). Slides were rinsed with PBS 1x 
and coverslips were mounted using anti-fading fluorescent 
mounting medium from DAKO (S3023).
Masson’s Trichrome
For Masson’s Trichrome staining, tissue was processed 
and sectioned according to the procedure described in the 
preparation of Immunofluorescence slides. Rehydration 
was also done as described in the Immunofluorescence 
section. Following rehydration slides were incubated with 
Bouins fixative solution containing 75% saturated picric 
acid (Sigma P6744), 25% of 37% formaldehyde solution 
(Sigma 252549) and 5% acetic acid (Sigma 33209) at 
room temperature overnight. After fixation nuclei were 
stained with Weigert’s hematoxylin solution containing 
0.5% hematoxylin (Sigma H9627), 0.5% concentrated 
HCl (Sigma 320331), 2% of a 29% ferric chloride solution 
(diluted from 45%) (Sigma 12322), and 47.5% (diluted from 
100%) ethanol (Sigma 02860) in distilled water for 10 min 
at room temperature. Slides were then rinsed under warm 
running tap water for 10 min, before they were rinsed in 
distilled water. The extra-nuclear tissue was then stained 
with the Biebrich Scarlet- Acid Fuchsin solution containing 
89% of a 1% Biebrich Scarlet solution (Sigma B6008), 
10% of a 1% Acid Fuchsin (Sigma F8129) solution and 
1% of acetic acid for 10 min at room temperature, followed 
by rinsing in distilled water until clear. To remove the 
stain from the collagen for differentiation, the slides were 
subsequently incubated with a solution containing 50% of 
a 5% phosphomolybdic acid solution (Sigma HT153) and 
50% of a 5% phosphotungstic acid solution (Sigma HT152) 
for 10 min at room temperature. Then slides were transferred 
to a solution containing 2.5% Aniline Blue (Sigma 415049) 
and 2% acetic acid in distilled water for 10 min at room 
temperature for counterstaining of collagen. Slides were then 
dehydrated rapidly in a succession of two baths of 1% acetic 
acid followed by 1 bath of 95% ethanol and two baths of 
100% ethanol. Slides were then left in a xylene bath until 
mounting in Eukitt® Quick-hardening mounting medium 
(Sigma 03989).
Statistical methods
All statistical analyses were performed in 
GraphPad®. Tumor growth experiments were analyzed 
using the Mann-Whitney test to compare the groups. The 
remaining experiments were analyzed using one-way 
ANOVA with a Fisher’s exact test for post hoc testing. 
In cases where there were only two groups to compare, a 
two-tailed t-Test was used. Significance is displayed using 
stars with one star meaning a resulting p-value of smaller 
than or equal to 0.05. Two stars means a p-value of smaller 
than or equal to 0.01. Three stars stands for a p-value of 
smaller than or equal to 0.001. If a p-value was greater 
than 0.05 the difference between the two concerned groups 
was regarded as not significant.
Ethics approval
Mice were kept, treated and euthanized according 
to the Swiss federal guidelines. The experimental protocol 
was approved by the Bernese cantonal ethical commission 
for animal experimentation (License number: BE120/13).
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